Sign In
Buy RETA
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Reata (RETA) Confirms Omaveloxolone NDA Filing in Q1 2022
10:55am, Friday, 01'st Oct 2021
Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its pre-NDA meeting with the FDA.
Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
06:45am, Thursday, 30'th Sep 2021
PLANO, Texas--(BUSINESS WIRE)---- $RETA--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it h
2 Biotech Stocks to Buy Right Now
09:31am, Sunday, 19'th Sep 2021
They both have great growth prospects.
Why Is Reata Pharmaceuticals, Inc. (RETA) Up 12.2% Since Last Earnings Report?
01:16pm, Wednesday, 08'th Sep 2021
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reata Pharmaceuticals, Inc. - RETA
06:11pm, Tuesday, 17'th Aug 2021
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA). Such i
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reata Pharmaceuticals, Inc. - RETA
09:23pm, Wednesday, 11'th Aug 2021
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA). Such investors are
Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat
11:38am, Tuesday, 10'th Aug 2021
Reata (RETA) beats estimates for earnings and sales. Stock down on negative regulatory update on lead pipeline candidate, bardoxolone.
RETA Stock Price Falls Over 10% Pre-Market: Why It Happened
06:25am, Tuesday, 10'th Aug 2021
The stock price of Reata Pharmaceuticals, Inc. (Nasdaq: RETA) fell by over 10% pre-market. This is why it happened.
Reata Pharmaceuticals' (RETA) CEO Warren Huff on Q2 2021 Results - Earnings Call Transcript
10:07pm, Monday, 09'th Aug 2021
Reata Pharmaceuticals' (RETA) CEO Warren Huff on Q2 2021 Results - Earnings Call Transcript
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates
06:28pm, Monday, 09'th Aug 2021
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 6.10% and 53.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the sto
Reata Pharmaceuticals: Q2 Earnings Insights
05:50pm, Monday, 09'th Aug 2021
Shares of Reata Pharmaceuticals (NASDAQ:RETA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 7.32% over the past year to ($1.3
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will report financial
Reata Pharmaceuticals, Inc. (RETA) Soars 5.3%: Is Further Upside Left in the Stock?
10:31am, Monday, 28'th Jun 2021
Reata Pharmaceuticals, Inc. (RETA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher i
Reata: Big Run-Up Toward Approval
03:59pm, Wednesday, 16'th Jun 2021
Reata Pharmaceuticals has enjoyed robust appreciation over the years, as the company advances two lead medicines (bardoxolone and omaveloxolone).
Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference
01:30pm, Monday, 07'th Jun 2021
PLANO, Texas, June 07, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced th
